Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) have a modified clinical presentation of venous thromboembolism (VTE) but also a worse prognosis than non-COPD patients with VTE. As it may induce therapeutic modifications, we evaluated the influence of the initial VTE presentation on the 3-month outcomes in COPD patients. METHODS: COPD patients included in the on-going world-wide RIETE Registry were studied. The rate of pulmonary embolism (PE), major bleeding and death during the first 3 months in COPD patients were compared according to their initial clinical presentation (acute PE or deep vein thrombosis (DVT)). RESULTS: Of the 4036 COPD patients included, 2452 (61%; 95% CI: 59.2-62.3) initially presented with PE. PE as the first VTE recurrence occurred in 116 patients, major bleeding in 101 patients and mortality in 443 patients (Fatal PE: first cause of death). Multivariate analysis confirmed that presenting with PE was associated with higher risk of VTE recurrence as PE (OR, 2.04; 95% CI: 1.11-3.72) and higher risk of fatal PE (OR, 7.77; 95% CI: 2.92-15.7). CONCLUSIONS: COPD patients presenting with PE have an increased risk for PE recurrences and fatal PE compared with those presenting with DVT alone. More efficient therapy is needed in this subtype of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Using the mortality observed in a cohort of 4036 patients with chronic obstructive pulmonary disease and VTE as baseline risk, 232 we estimated that the use of IVC filters for patients with significant preexisting cardiopulmonary disease may lead to 16 more deaths per 1000 (95% CI, 19 fewer to 66 more; low-certainty evidence).”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [232]
The cited source says what the claim attributes to it.
In the citing paper
“Using the baseline risk of PE observed in a cohort of 4036 patients with chronic obstructive pulmonary disease and VTE, 232 we estimated that the use of an IVC filter may lead to 13 fewer PEs (95% CI, 23 fewer to 10 more; low-certainty evidence).”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [232]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248 · cited 1×
“0%, three-time higher than in a recent randomized control trial including stable COPD patients [20] and as high as that one observed in COPD patients admitted in a respiratory intensive care unit for a severe exacerbation”
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationGuidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Buist, A. S., McBurnie, M. A., Vollmer, W. M., Gillespie, S., Burney, P., Mannino, D. M., Menezes, A. M., Sullivan, S. D., Lee, T. A., Weiss, K. B., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61377-4 · Cited by 2,366 · cited 1×
“Background Chronic obstructive pulmonary disease (COPD) is a common and severe medical condition: it affects more than 10% of people over 40 years old [1] and the World Health Organization estimates it will become the fourth leading cause of death in 2030 worldwide [2].”
BackgroundThe Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310 · cited 1×
“DVT is two times more frequent than PE in the general setting, whereas PE have a higher risk of death [5].”
BackgroundGlobal burden of COPD: systematic review and meta-analysis
Halbert, R. J., Natoli, J. L., Gano, A., Badamgarav, E., Buist, A. S., & Mannino, D. M. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00124605 · Cited by 1,499 · cited 1×
“The prevalence of COPD in the RIETE registry is similar to prevalence of COPD in general setting [29].”
Background
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Streiff, M. B., Holmstrom, B., Angelini, D. E., Ashrani, A. A., Elshoury, A., Fanikos, J. R., Fertrin, K. Y., Fogerty, A. E., Gao, S., Goldhaber, S. Z., et al. (2021) · PubMed · doi:10.6004/jnccn.2021.0047 · Cited by 225
Management of the COPD Patient with Comorbidities: An Experts Recommendation Document
Iglesias, J. R., Díez‐Manglano, J., García, F. L., Peromingo, J. A. D., Almagro, P., & Aguilar, J. M. V. (2020) · International Journal of COPD · doi:10.2147/copd.s242009 · Cited by 82
Bertoletti, L., & Humbert, M. J. C. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.10.005 · Cited by 53
Self-citationPulmonary Embolism in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Cao, Y., Dong, L., & Cao, J. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.235865 · Cited by 47
“[17] A total of 172 AE‑COPD hospitalized patients were enrolled in a prospective study in Turkey, and the prevalence of PE in these patients was 29.1%,[20] with all the patients complicated with DVT. Tillie‑Leblond et al.[22] found that in France, the incidence of PE was 25% in patients with severe COPD exacerbation o…”
BackgroundInfluential
Metadata
- Authors
- Bertoletti, L., Quenet, S., Laporte, S., Sahuquillo, J., Conget, F., Pedrajas, J., Martin, M., Casado, I., Riera-Mestre, A., Monreal, M., & The RIETE Investigators
- Affiliations
- Inserm (FR)
- Université Jean Monnet (FR)
- Hospital Municipal de Badalona (ES)
- Hospital Clínico Universitario Lozano Blesa (ES)
- Hospital Clínico San Carlos (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Bellvitge University Hospital (ES)
- Corresponding author
- Bertoletti, Laurent
- Venue
- Respiratory Research
- Published
- 2013
- Volume
- 14
- Issue
- 1
- Pages
- 75
- ISSN
- 1465-9921 (ISSN-L)
- PMC
- PMC3728047
- OpenAlex
- W2113940702
- Cited by
- 56
- References
- 34
- Citations by year
- 2025: 5 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 11 · 2020: 10 · 2019: 1 · 2018: 5 · 2017: 5 · 2016: 2 · 2015: 6 · 2014: 3
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Respiratory Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Sanofi
- Sanofi España
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- pulmonary embolism, venous thromboembolism, chronic obstructive pulmonary disease, deep vein thrombosis, VTE recurrence, fatal pulmonary embolism, major bleeding, mortality, first clinical manifestation, RIETE registry
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Prognosis, Pulmonary Embolism, Registries, Cohort Studies, Comorbidity, Prevalence, Survival Rate, Survival Analysis, Risk Assessment, Pulmonary Disease, Chronic Obstructive, Internationality, Venous Thromboembolism, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. https://app.cochat.ai/papers/10.1186/1465-9921-14-75
- The paper
- Bertoletti, L., Quenet, S., Laporte, S., Sahuquillo, J., Conget, F., Pedrajas, J., Martin, M., Casado, I., Riera-Mestre, A., Monreal, M., & The RIETE Investigators. (2013). Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. Respiratory Research. https://doi.org/10.1186/1465-9921-14-75
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


